嵌合抗原受体
电穿孔
逆转录病毒
遗传增强
转座酶
载体(分子生物学)
生物
计算生物学
基因
转座因子
病毒学
癌症
免疫疗法
遗传学
重组DNA
基因组
作者
Diyuan Qin,Yong Huang,Dan Li,Yongsheng Wang,Wei Wang,Yuquan Wei
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2016-09-01
卷期号:27 (8): 711-722
被引量:18
标识
DOI:10.1097/cad.0000000000000387
摘要
T-lymphocytes genetically engineered with the chimeric antigen receptor (CAR-T) have shown great therapeutic potential in cancer treatment. A variety of preclinical researches and clinical trials of CAR-T therapy have been carried out to lay the foundation for future clinical application. In these researches, several gene-transfer methods were used to deliver CARs or other genes into T-lymphocytes, equipping CAR-modified T cells with a property of recognizing and attacking antigen-expressing tumor cells in a major histocompatibility complex-independent manner. Here, we summarize the gene-transfer vectors commonly used in the generation of CAR-T cell, including retrovirus vectors, lentivirus vectors, the transposon/transposase system, the plasmid-based system, and the messenger RNA electroporation system. The following aspects were compared in parallel: efficiency of gene transfer, the integration methods in the modified T cells, foreground of scale-up production, and application and development in clinical trials. These aspects should be taken into account to generate the optimal CAR-gene vector that may be suitable for future clinical application.
科研通智能强力驱动
Strongly Powered by AbleSci AI